Meeting
2019 ASCO Annual Meeting
A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Authors
Davide Melisi
University of Verona, Verona, Italy
Davide Melisi , Antoine Hollebecque , Do-Youn Oh , Emiliano Calvo , Anna M. Varghese , Erkut Hasan Borazanci , Teresa Macarulla Mercade , Francesca Simionato , Joon Oh Park , Johanna C. Bendell , Sandrine J. Faivre , Yumin Zhao , Ivelina Gueorguieva , Michael Man , Shawn Estrem , Karim Adnane Benhadji , Mark Lanasa , Susan C. Guba , Rocio Garcia-Carbonero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02734160
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4124)
DOI
10.1200/JCO.2019.37.15_suppl.4124
Abstract #
4124
Poster Bd #
229
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
![Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.](https://d201v5jt9ylckg.cloudfront.net/195/11777/139522/139522_poster_pv.jpg)
Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.
First Author: Davide Melisi
Poster
2022 ASCO Annual Meeting
A phase 1/2 study of DCC‑3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.
First Author: Anthony W. Tolcher
Poster
2021 ASCO Annual Meeting
BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first‑line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).
First Author: Peter Schmid
Poster
2019 ASCO Annual Meeting
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
First Author: Zahi Ibrahim Mitri